Johnson & Johnson's Spravato, an esketamine nasal spray for treatment-resistant depression, posted $468 million in global sales in Q1 2026, a 46% increase year-over-year. This growth signals strong market acceptance of psychedelic therapies, encouraging investors and analysts about the sector's potential. Jefferies projects Spravato sales could reach $3 billion by 2027 and $3.5 billion by 2028, with peak sales up to $5 billion. The success of Spravato supports the commercial viability of psychedelics, benefiting companies like AtaiBeckley, whose similar intranasal treatments fit existing treatment models. Continued investment in infrastructure and upcoming clinical milestones across the psychedelics industry suggest growing momentum and Big Pharma interest.
Johnson & Johnson reported strong Q2 sales of $584 million for Spravato, a nasal spray for treatment-resistant depression, signaling robust market potential for psychedelic drugs. Jefferies highlights this growth supports the commercial viability of ...
Johnson & Johnson reported solid Q2 2026 results, achieving 6.6% annual revenue growth driven by strong Pharma and MedTech divisions. The company maintains a portfolio of over 15 blockbuster drugs and a promising pipeline, supporting its status as a ...
Johnson & Johnson reported better-than-expected Q2 2026 results with adjusted EPS of $2.90, surpassing estimates, and revenue of $25.31 billion, driven by strong pharmaceutical sales. Key growth came from the Innovative Medicine segment, with notable...
The FTSE 100 dropped 23 points to 10,506, pressured by mining stocks reacting to China's slower-than-expected 4.3% GDP growth in Q2, its weakest in three years. European markets also declined, while US futures rose, led by tech. PayPal shares surged ...
US stock futures rose after a softer-than-expected Consumer Price Index (CPI) report reduced the chances of a Federal Reserve rate hike in July. The market now awaits today's Producer Price Index (PPI) data, which could either confirm easing inflatio...
